TITLE

NOBEX/BIOCON TO DEVELOP ORAL INSULIN PRODUCT

PUB. DATE
December 2004
SOURCE
Worldwide Biotech;Dec2004, Vol. 16 Issue 12, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the joint drug development agreement entered into by Nobex Corporation with India-based biotechnology firm Biocon Limited. Diabetes treatment which will be the focus of the collaboration; Remarks from Kiran Mazumdar-Shaw, chairman and managing director of Biocon, regarding the joint agreement.
ACCESSION #
15231064

 

Related Articles

  • Biocon plans to acquire Nobex's IP assets.  // Chemical Business;Dec2005, Vol. 19 Issue 12, p43 

    This article reports on the plan of Bangalore, India-based Biocon to acquire the intellectual property of its research collaborator Nobex Corp., as of December 2005. The amount invested by Biocon in Nobex is presented. Kiran Mazumdar-Shaw, CEO of Biocon, expressed her views on the plan....

  • Profile: Kiran Mazumdar-Shaw. Jayaraman, K.S. // Nature Biotechnology;Jan2005, Vol. 23 Issue 1, p11 

    This article focuses on Kiran Mazumdar-Shaw, CEO of Biocon Ltd. Breaking molds and records along the way, Kiran Mazumdar-Shaw is on a single-minded mission to put Indian biotechnology on the map. When Biocon raised $65 million in a flotation last March, an initial public offering oversubscribed...

  • Of a Different DNA.  // Business Today;9/1/2011, Vol. 20 Issue 18, p82 

    The article features Kiran Mazumdar-Shaw, chairman and managing director of Biocon Inc., the first biotechnology company in India. According to Mazumdar-Shaw, who is one of the richest women in India, she is a self-taught entrepreneur wherein Raghunath Mashelkar, doctor Devi Shetty, and banker...

  • SANS PFIZER, BIOCON STAYS BUOYANT. Das, Goutam // Business Today;4/15/2012, Vol. 21 Issue 8, p52 

    The article discusses market position of Biocon, the largest biotechnology company in India, after the world's largest drug maker Pfizer cancelled its partnership with it. According to Kiran Mazumdar-Shaw from Biocon, the firm will still take its products to the global markets in a different...

  • FIRST LADY. Mazumdar, Sudip // Newsweek (Atlantic Edition);10/11/2004 (Atlantic Edition), Vol. 144 Issue 15, p59 

    Presents an interview with Kiran Mazumdar-Shaw, founder of India's Biocon Ltd. and richest woman in India. Thoughts on Singapore's biotechnological platform, and need for a human resources based model for business; Opinion on the capacity for Asian pharmaceutical companies to become global...

  • First Lady. Mazumdar, Sudip // Newsweek;10/18/2004, Vol. 144 Issue 16, pE40 

    Presents an interview with Kiran Mazumdar-Shaw, founder of India's Biocon Ltd. and richest woman in India. Thoughts on Singapore's biotechnological platform, and need for a human resources based model for business; Opinion on the capacity for Asian pharmaceutical companies to become global...

  • FIRST LADY. Mazumdar, Sudip // Newsweek (Pacific Edition);10/11/2004 (Pacific Edition), Vol. 144 Issue 15, p39 

    Presents an interview with Kiran Mazumdar-Shaw, founder of India's Biocon Ltd. and richest woman in India. Thoughts on Singapore's biotechnological platform, and need for a human resources based model for business; Opinion on the capacity for Asian pharmaceutical companies to become global...

  • Kiran Mazumdar-Shaw. SACHITANAND, RAHUL // Business Today;10/7/2007, Vol. 16 Issue 20, p82 

    The article profiles Kiran Mazumdar-Shaw, owner of Biocon Ltd. and the second richest woman in India. She is portrayed as a strong woman when she have to deal with her husband's hospitalization and business at the same time. It cites that her passion, energy, conviction and being ambitious have...

  • Biocon's novel anti-psoriasis biotech drug released in India. SURESH, N.; GUNASHEKAR, RAJ // BioSpectrum;Sep2013, Vol. 11 Issue 9, p12 

    The article reports on the launching of a cheaper and novel anti-psoriasis drug from biotech company Biocon India Ltd. in India. Biocon has commercialized its novel biological drug development of a monoclonal antibody-based drug Itolizumab under the brand name Alzumab. Chief medical director...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics